Dosimetric factors predictive of late toxicity in prostate cancer radiotherapy;Radiothérapie prostatique : Prédiction de la toxicité tardive à partir des données dosimétriques

Cancer/Radiotherapie

Volumn 14, Issue 6-7, 2010, Pages 460-468

  de Crevoisier, R ^a,b   Fiorino, C ^c   Dubray, B ^d,e  

^a CENTRE EUGÈNE MARQUIS   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d CENTRE HENRI BECQUEREL   (France)

^e Thoracic oncology and respiratory intensive care   (France)

Author keywords

Modelling; Normal tissue complications; Prostate; Radiotherapy

Indexed keywords

ACCURACY; BLADDER; BONE DISEASE; CANCER PATIENT; CANCER RADIOTHERAPY; CONE BEAM COMPUTED TOMOGRAPHY; DOSIMETRY; FEMUR HEAD; HUMAN; IONIZING RADIATION; MATHEMATICAL MODEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION HAZARD; RECTUM HEMORRHAGE; RECTUM INJURY; RISK FACTOR; SEXUAL DYSFUNCTION; SHORT SURVEY; THREE DIMENSIONAL IMAGING; URINARY TRACT INJURY; ADENOCARCINOMA; ANTIBODY SPECIFICITY; ERECTILE DYSFUNCTION; GENETICS; MALE; ORGAN SIZE; PROSTATE TUMOR; RADIATION INJURY; RADIATION RESPONSE; RADIOMETRY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECTUM; REVIEW; SPINE; THEORETICAL MODEL; TIME;

ADENOCARCINOMA; CONE-BEAM COMPUTED TOMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, RADIATION; ERECTILE DYSFUNCTION; FEMUR HEAD; HUMANS; MALE; MODELS, THEORETICAL; ORGAN SIZE; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOMETRY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTUM; RISK FACTORS; SPINE; TIME FACTORS; URINARY BLADDER;

EID: 77958176753     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.07.225     Document Type: Short Survey

References (87)

1. Al-Mamgani A., Heemsbergen W.D., Peeters S.T., Lebesque J.V. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:685-691.
2. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., van Leenders G.J., Slot A., Dielwart M.F., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:980-988.
3. Amdur R.J., Parsons J.T., Fitzgerald L.T., Million R.R. Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up. Radiother Oncol 1990, 18:235-246.
4. Azria D., Aillères N., Llacer Moscardo C., Hay M.H., Dubois J.B., Fenoglietto P. Radiothérapie de conformation avec modulation d'intensité dans le cancer de prostate: vers un nouveau standard. Cancer Radiother 2009, 13:409-415.
5. Beckendorf V., Guerif S., Le Prise E., Cosset J.M., Lefloch O., Chauvet B., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004, 60:1056-1065.
6. Beckendorf V., Guérif S., Le Prisé é., Cossett J.M., Le Floch O., Chauvet B., et al. Late toxicity in the GETUG 06 randomized trial comparing 70 Gy and 80 Gy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 69:S319.
7. Bedford J.L., Khoo V.S., Webb S., Dearnaley D.P. Optimization of coplanar six-field techniques for conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2000, 46:231-238.
8. Bentzen S.M., Constine L.S., Deasy J.O., Eisbruch A., Jackson A., Marks L.B., et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010, 76:S3-9.
9. Boersma L.J., van den Brink M., Bruce A.M., Shouman T., Gras L., te Velde A., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998, 41:83-92.
10. Burman C., Kutcher G.J., Emami B., Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991, 21:123-135.
11. Burri R.J., Stock R.G., Cesaretti J.A., Atencio D.P., Peters S., Peters C.A., et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 2008, 170:49-59.
12. Buyyounouski M.K., Horwitz E.M., Price R.A., Hanlon A.L., Uzzo R.G., Pollack A. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys 2004, 58:743-749.
13. Buyyounouski M.K., Horwitz E.M., Uzzo R.G., Price R.A., McNeeley S.W., Azizi D., et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 2004, 59:1383-1391.
14. Cahlon O., Hunt M., Zelefsky M.J. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol 2008, 18:48-57.
15. Cahlon O., Zelefsky M.J., Shippy A., Chan H., Fuks Z., Yamada Y., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71:330-337.
16. Chapet O., Kong F.M., Lee J.S., Hayman J.A., Ten Haken R.K. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 2005, 77:176-181.
17. Cheung R., Tucker S.L., Ye J.S., Dong L., Liu H., Huang E., et al. Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1513-1519.
18. Cozzarini C., Fiorino C., Ceresoli G.L., Cattaneo G.M., Bolognesi A., Calandrino R., et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 2003, 55:688-694.
19. Dale E., Olsen D.R., Fossa S.D. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 1999, 43:385-391.
20. Damaraju S., Murray D., Dufour J., Carandang D., Myrehaug S., Fallone G., et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006, 12:2545-2554.
21. de Crevoisier R, Chira C, Lafond C, Crouzet L, Simon A, Louvel G, et al. Benefit of IMRT in high-dose prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2010 [in press, abstract ASTRO].
22. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-122.
23. Feigenberg S.J., Hanlon A.L., Horwitz E.M., Uzzo R.G., Eisenberg D., Pollack A. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2005, 62:397-405.
24. Fellin G., Fiorino C., Rancati T., Vavassori V., Baccolini M., Bianchi C., et al. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol 2009, 93:197-202.
25. Fiorino C., Cozzarini C., Vavassori V., Sanguineti G., Bianchi C., Cattaneo G.M., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 2002, 64:1-12.
26. Fiorino C., Fellin G., Rancati T., Vavassori V., Bianchi C., Borca V.C., et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 2008, 70:1130-1137.
27. Fiorino C., Sanguineti G., Cozzarini C., Fellin G., Foppiano F., Menegotti L., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 2003, 57:953-962.
28. Fiorino C., Valdagni R., Rancati T., Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009, 93:153-167.
29. Fisch B.M., Pickett B., Weinberg V., Roach M. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001, 57:955-959.
30. Fonteyne V., De Neve W., Villeirs G., De Wagter C., De Meerleer G. Late Radiotherapy-Induced Lower Intestinal Toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 2007, 84:156-163.
31. Fransson P., Bergstrom P., Lofroth P.O., Widmark A. Prospective evaluation of urinary and intestinal side effects after BeamCath stereotactic dose-escalated radiotherapy of prostate cancer. Radiother Oncol 2002, 63:239-248.
32. Greco C., Mazzetta C., Cattani F., Tosi G., Castiglioni S., Fodor A., et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol 2003, 69:215-222.
33. Gulliford S.L., Foo K., Morgan R.C., Aird E.G., Bidmead A.M., Critchley H., et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010, 76:747-754.
34. Heemsbergen WD, Al-Mamgani A, Witte MG, van Herk M, Pos FJ, Lebesque JV. Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys 2010 [; in press]. http://dx.doi.org/10.1016/j.ijrobp.2009.07.1680.
35. Herold D.M., Hanlon A.L., Hanks G.E. Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 1999, 43:475-479.
36. Huang E.H., Pollack A., Levy L., Starkschall G., Dong L., Rosen I., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002, 54:1314-1321.
37. Incrocci L. Radiation therapy for prostate cancer and erectile (dys) function: the role of imaging. Acta Oncol 2005, 44:673-678.
38. Incrocci L., Slob A.K. Incidence, etiology, and therapy for erectile dysfunction after external beam radiotherapy for prostate cancer. Urology 2002, 60:1-7.
39. Jackson A., Skwarchuk M.W., Zelefsky M.J., Cowen D.M., Venkatraman E.S., Levegrun S., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001, 49:685-698.
40. Kiteley R.A., Lee W.R., deGuzman A.F., Mirzaei M., McCullough D.L. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy 2002, 1:90-94.
41. Kuban D.A., Tucker S.L., Dong L., Starkschall G., Huang E.H., Cheung M.R., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
42. Kupelian P.A., Thakkar V.V., Khuntia D., Reddy C.A., Klein E.A., Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005, 63:1463-1468.
43. Kutcher G.J., Burman C., Brewster L., Goitein M., Mohan R. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 1991, 21:137-146.
44. Leborgne F., Fowler J. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison. Int J Radiat Oncol Biol Phys 2009, 74:1441-1446.
45. Liu M., Pickles T., Agranovich A., Berthelet E., Duncan G., Keyes M., et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 2004, 58:59-67.
46. Lu Y., Song P.Y., Li S.D., Spelbring D.R., Vijayakumar S., Haraf D.J., et al. A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 1995, 33:1121-1125.
47. Luo C., Yang C.C., Narayan S., Stern R.L., Perks J., Goldberg Z., et al. Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:1253-1262.
48. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985, 8:S13-S19.
49. Lyman J.T., Wolbarst A.B. Optimization of radiation therapy. III: a method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987, 13:103-109.
50. Lyman J.T., Wolbarst A.B. Optimization of radiation therapy. IV: a dose-volume histogram reduction algorithm. Int J Radiat Oncol Biol Phys 1989, 17:433-436.
51. Macdonald A.G., Bissett J.D. Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy. Clin Oncol (R Coll Radiol) 2001, 13:135-137.
52. Mangar S.A., Sydes M.R., Tucker H.L., Coffey J., Sohaib S.A., Gianolini S., et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol 2006, 80:355-362.
53. Marks L.B., Yorke E.D., Jackson A., Ten Haken R.K., Constine L.S., Eisbruch A., et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010, 76:S10-S19.
54. Merrick G.S., Butler W.M., Dorsey A.T., Lief J.H., Donzella J.G. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2000, 48:1069-1074.
55. Michalski J.M., Winter K., Purdy J.A., Perez C.A., Ryu J.K., Parliament M.B., et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 2004, 58:735-742.
56. Mohan R., Mageras G.S., Baldwin B., Brewster L.J., Kutcher G.J., Leibel S., et al. Clinically relevant optimization of 3-D conformal treatments. Med Phys 1992, 19:933-944.
57. Munbodh R., Jackson A., Bauer J., Schmidtlein C.R., Zelefsky M.J. Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity modulated radiation therapy for prostate cancer. Med Phys 2008, 35:2137-2150.
58. Peeters S.T., Heemsbergen W.D., van Putten W.L., Slot A., Tabak H., Mens J.W., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 1019-1034.
59. Peeters S.T., Heemsbergen W.D., van Putten W.L., Slot A., Tabak H., Mens J.W., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 61:1019-1034.
60. Peeters S.T., Hoogeman M.S., Heemsbergen W.D., Hart A.A., Koper P.C., Lebesque J.V. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 2006, 66:11-19.
61. Rancati T., Fiorino C., Gagliardi G., Cattaneo G.M., Sanguineti G., Borca V.C., et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 2004, 73:21-32.
62. Rezvoy N, Dubray B. Probabilités de lésion des organes à risque : historique et principaux modèles mathématiques d'estimation. Radiother Oncol 2010;14(4-5):241-5.
63. Roach M., Winter K., Michalski J.M., Cox J.D., Purdy J.A., Bosch W., et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 2004, 60:1351-1356.
64. Saad F., Clarke N., Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006, 49:429-440.
65. Sanguineti G., Agostinelli S., Foppiano F., Franzone P., Garelli S., Marcenaro M., et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 2002, 86:1843-1847.
66. Selek U., Cheung R., Lii M., Steadham R.E., Vantreese T.R., Little D.J., et al. Erectile dysfunction and radiation dose to penile base structures: a lack of correlation. Int J Radiat Oncol Biol Phys 2004, 59:1039-1046.
67. Singh A.K., Guion P., Sears-Crouse N., Ullman K., Smith S., Albert P.S., et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol 2007, 2:36.
68. Skwarchuk M.W., Jackson A., Zelefsky M.J., Venkatraman E.S., Cowen D.M., Levegrün S., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000, 47:103-113.
69. Sohn M., Yan D., Liang J., Meldolesi E., Vargas C., Alber M. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys 2007, 67:1066-1073.
70. Stasi M., Munoz F., Fiorino C., Pasquino M., Baiotto B., Marini P., et al. Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol 2006, 80:363-370.
71. Storey M.R., Pollack A., Zagars G., Smith L., Antolak J., Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48:635-642.
72. Syndikus I., Morgan R.C., Sydes M.R., Graham J.D., Dearnaley D.P. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 Trial (Isrctn47772397). Int J Radiat Oncol Biol Phys 2009.
73. Tucker S., Dong L., Bosch W., Lee A., Kuban D. Fit of a generalized Lyman Normal tissue complication probability (NTCP) model to grade P 2 late rectal toxicity data from patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 2007, 69:S8-9.
74. Tucker S.L., Cheung R., Dong L., Liu H.H., Thames H.D., Huang E.H., et al. Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:353-365.
75. Tucker S.L., Dong L., Cheung R., Johnson J., Mohan R., Huang E.H., et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60:1589-1601.
76. Valdagni R., Rancati T., Fiorino C. Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. Cancer 2009, 115:3141-3149.
77. Valdagni R., Rancati T., Ghilotti M., Cozzarini C., Vavassori V., Fellin G., et al. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2009, 74:1431-1440.
78. van Lin E.N., Futterer J.J., Heijmink S.W., van der Vight L.P., Hoffmann A.L., van Kollenburg P., et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006, 65:291-303.
79. Vargas C., Martinez A., Kestin L.L., Yan D., Grills I., Brabbins D.S., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:1297-1308.
80. Wachter S., Gerstner N., Goldner G., Potzi R., Wambersie A., Potter R. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol 2001, 59:65-70.
81. Wernicke A.G., Valicenti R., Dieva K., Houser C., Pequignot E. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:1357-1363.
82. Wu Q., Mohan R., Niemierko A., Schmidt-Ullrich R. Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys 2002, 52:224-235.
83. Zelefsky M.J., Cowen D., Fuks Z., Shike M., Burman C., Jackson A., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999, 85:2460-2468.
84. Zelefsky M.J., Eid J.F. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998, 40:129-133.
85. Zelefsky M.J., Fuks Z., Hunt M., Yamada Y., Marion C., Ling C.C., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53:1111-1116.
86. Zelefsky M.J., Levin E.J., Hunt M., Yamada Y., Shippy A.M., Jackson A., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
87. Zietman A.L., DeSilvio M.L., Slater J.D., Rossi C.J., Miller D.W., Adams J.A., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239.